MedTrace Logo

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

NCT03348059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2017-11-20

No results posted yet for this study

Summary

The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment

Conditions

  • Chronic Hepatitis c

Interventions

DRUG

Direct-acting antiviral therapy

HCV patients received direct-acting antiviral treatment for 12 or 24 weeks

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2016-11-30
Completion
2017-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03348059 on ClinicalTrials.gov